Omeros Corporation Share Price Today: Live Updates & Key Insights

Omeros Corporation share price today is $11.04, up -1.08%. The stock opened at $11.115 against the previous close of $11.12, with an intraday high of $11.21 and low of $10.89.

Omeros Corporation Share Price Chart

Omeros Corporation

us-stock
To Invest in {{usstockname}}
us-stock

Omeros Corporation Share Price Performance

$11.04 -0.0108(-1.08%) OMER at 23 Mar 2026 02:36 PM Biotechnology
Lowest Today 10.89
Highest Today 11.21
Today’s Open 11.115
Prev. Close 11.12
52 Week High 17.65
52 Week Low 2.95
Day’s Range: Low 10.89 High 11.21
52-Week Range: Low 2.95 High 17.65
1 day return -
1 Week return -0.8
1 month return -3.58
3 month return +15.86
6 month return +155.61
1 year return +22.28
3 year return +206.81
5 year return -44.06
10 year return -

Omeros Corporation Institutional Holdings

BlackRock Inc 6.28

Vanguard Group Inc 5.66

Ingalls & Snyder LLC 4.86

Vanguard Total Stock Mkt Idx Inv 2.96

Morgan Stanley - Brokerage Accounts 2.81

Stifel Financial Corp 2.56

Geode Capital Management, LLC 2.30

iShares Russell 2000 ETF 2.29

State Street Corp 1.75

JPMorgan Chase & Co 1.17

Vanguard Institutional Extnd Mkt Idx Tr 1.08

D. E. Shaw & Co LP 1.06

Susquehanna International Group, LLP 1.05

UBS Group AG 1.00

Fidelity Small Cap Index 0.91

CI Private Wealth LLC 0.86

Charles Schwab Investment Management Inc 0.84

Bank of Montreal 0.79

BMO Capital Markets Corp. 0.79

Royal Bank of Canada 0.77

Northern Trust Corp 0.76

Two Sigma Investments LLC 0.74

iShares Russell 2000 Growth ETF 0.70

Jane Street Group LLC 0.65

Millennium Management LLC 0.62

State St Russell Sm/Mid Cp® Indx SL Cl I 0.56

Fidelity Extended Market Index 0.52

Schwab US Small-Cap ETF™ 0.48

State Street® SPDR® S&P® PhrmctlsETF 0.45

Vanguard Russell 2000 ETF 0.44

State St Russell Sm Cap® Indx SL Cl I 0.31

Vanguard Health Care ETF 0.29

iShares US Pharmaceuticals ETF 0.27

Blackrock Extended Mkt Fund CF 0.26

iShares Micro-Cap ETF 0.25

Schwab Small Cap Index 0.23

Extended Equity Market Fund K 0.22

NT R2000 Index Fund - NL 0.21

iShares Core S&P Total US Stock Mkt ETF 0.19

Fidelity Total Market Index 0.19

Omeros Corporation Market Status

Strong Buy: 1

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

Omeros Corporation Fundamentals

Market Cap 779.91 M

PB Ratio 8.4414

PE Ratio 0.0

Enterprise Value 943.94 M

Total Assets 277.08 M

Volume 1318574

Omeros Corporation Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:73813000 73.8M, FY19:111805000 111.8M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:0 0.0M, FY20:72911000 72.9M, FY19:110940000 110.9M

Annual Net worth FY23:19988000 20.0M, FY22:28777000 28.8M, FY21:194235000 194.2M, FY20:-138061000 -138.1M, FY19:-106906000 -106.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:412000 0.4M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-10293000 -10.3M, Q1/2025:-301000 -0.3M, Q3/2024:null 0.0M, Q2/2024:-208000 -0.2M

Quarterly Net worth Q3/2025:-30917000 -30.9M, Q2/2025:-25424000 -25.4M, Q1/2025:-33460000 -33.5M, Q3/2024:-32232000 -32.2M, Q2/2024:-56041000 -56.0M

About Omeros Corporation & investment objective

Company Information Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Organisation Biotechnology

Employees 202

Industry Biotechnology

CEO Dr. Gregory A. Demopulos M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Omeros Corporation FAQs

What is the share price of Omeros Corporation today?

The current share price of Omeros Corporation is $11.04.

Can I buy Omeros Corporation shares in India?

Yes, Indian investors can buy Omeros Corporation shares by opening an international trading and demat account with Motilal Oswal.

How to buy Omeros Corporation shares in India?

You can easily invest in Omeros Corporation shares from India by:

Can I buy fractional shares of Omeros Corporation?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Omeros Corporation?

Omeros Corporation has a market cap of $779.91 M.

In which sector does Omeros Corporation belong?

Omeros Corporation operates in the Biotechnology sector.

What documents are required to invest in Omeros Corporation stocks?

To invest, you typically need:

What is the PE and PB ratio of Omeros Corporation?

The PE ratio of Omeros Corporation is N/A and the PB ratio is 8.44.